The Global Next Generation Cancer Diagnostics Market employs advanced technologies such as next-generation sequencing, liquid ...

Market Growth Driven by Advancements in Genomic Research, Rising Demand for Personalized Medicine, and Key Applications in ...

Discover how precision medicine and immunotherapy are transforming cancer treatment by utilizing genetic profiling and advanced sequencing techniques to provide personalized, targeted care with fewer ...

One key trend is the integration of molecular diagnostics such as next-generation sequencing. The increasing global incidence ...

Emerging technologies leveraging ctDNA and NGS are increasing our ability to identify cancers in high-risk patients, which was previously beyond reach,” said Dr. Nathan Montgomery, Vice President of ...

About Ignite Proteomics Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., specializes in advanced RPPA technology for cancer diagnostics. As the only provider of a CLIA-accredited RPPA assay ...

The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.

AI and biophysics are revolutionizing cancer treatment by predicting protein binding sites for personalized therapies.

Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.

Vazyme (688105), a leading life science technology company, significantly contributed to groundbreaking research published in ...